Curriculum Vitae

EDUCATION

1987 – 1991 M.D., Hahnemann University School of Medicine, Philadelphia, PA
1985 – 1987 Wellesley College, Wellesley, MA
Post–baccalaureate Pre-medical Program
1985 – 1986 Harvard University, Cambridge, MA
Post–baccalaureate Pre-medical Program
1979 – 1983 BA, Connecticut College, New London, CT
Major in Economics, Minor in English Literature

POSTDOCTORAL TRAINING

July 1995 – June 1997 Research and Clinical Addiction Medicine Fellow; Director, Marc Galanter, M.D. Department of Psychiatry, New York University Medical Center, New York, NY
February 1995 – February 1996 Psychoanalytic Psychotherapy Fellow, Columbia University Psychoanalytic Institute; Director, Don Meyers, M.D.
Columbia University and Medical Center, College of Physicians and surgeons, New York, NY
July 1994 – June 1995 Chief Resident, Department of Psychiatry (PGY IV), New York University Medical Center, New York, NY
July 1992 – June 1995 Resident, General Psychiatry (PGY II-IV), New York University Medical Center, New York, NY
July 1991 – June 1992 Intern, Departments of Medicine and Psychiatry (PGY I), New York University Medical Center, New York, NY

LICENSURES

1993 – Present New York State Department of Health, Bureau of Controlled Substances, DEA #BK37094600
1992 – Present State of New York, Medical and Surgical License #190563

SPECIALTY CERTIFICATIONS

1996 Certified by the American Board of Psychiatry and Neurology in Psychiatry, Number 42498
1998 Certified by the American Board of Psychiatry and Neurology for subspecialty certification in Addiction Psychiatry

ACADEMIC APPOINTMENTS

July 1998 – Present Assistant Clinical Professor of Psychiatry, College of Physicians & Surgeons of Columbia University, New York, NY
November 1998 – Present Adjunct Assistant Professor of Psychiatry and Behavioral Sciences, New York Medical College, New York, NY
July 1997 – June 1998 Assistant Professor of Psychiatry, Albert Einstein College of Medicine, New York, NY
July 1994 – June 1997 Clinical Instructor in Psychiatry, New York University Medical Center, New York, NY

PRIVATE PRACTICE

July1995 – Present Solo Private Practice in Psychopharmacology, Addiction Medicine and Psychodynamic Psychotherapy

RESEARCH PRACTICE

August 2002 – Present Director of Bioscience Research, LLC

HOSPITAL AND CLINICAL APPOINTMENTS

August 2000 – Present Medical Staff of the Department of Psychiatry and Behavioral Sciences at Saint Vincent’s Hospital and Medical Center, New York, NY
October 1999 – Present Attending Physician; Research Consultant, Department of Psychiatry, Saint Vincent’s Hospital and Medical Center, New York, NY
January 1999 – Sept. 1999 Medical Director, Alcohol and Parole Treatment Programs, Greenwich House, New York, NY
July 1997 – December 1998 Medical Director and Chief Psychiatrist, National Institute on Drug Abuse Grant # 5R01DA09583-02, "Imipramine and Relapse Prevention in Depressed Methadone Patients," Psychiatric Institute, Columbia University and Medical Center, College of Physicians and Surgeons, New York, NY
November 1997 – Present Official Evaluation and Treatment Provider for the Committee for Physicians’ Health of the Medical Society of the State of New York
November 1997 – Present Official Evaluation and Treatment Provider for the Office of Professional Medical Conduct of the New York State Department of Health
July 1997 – December 1998 Attending Psychiatrist, Department of Psychiatry, Beth Israel Medical Center, New York, NY
July 1995 – 1996 Medical Director, Cocaine Clinic, Bellevue Hospital and the New York University Medical Center, New York, NY
July 1995 – June 1997 Attending Psychiatrist, New York University Medical Center, New York, NY
July 1995 – June 1997 Attending Psychiatrist, Bellevue Hospital and Medical Center, New York, NY
July 1994 – June 1995 Chief Resident, Department of Psychiatry, New York University Medical Center, New York, NY
July 1992 – June 1995 Resident, Department of Psychiatry, New York University Medical Center, New York, NY
July 1991 – June 1992 Intern, Department of Psychiatry and Department of Medicine, New York University Medical Center, New York, NY

TEACHING EXPERIENCE

September 1998 – Present "Psychiatric Medicine I and Psychiatric Medicine II," a year-long course taught to the first and second year Medical Students at the College of Physicians and Surgeons of Columbia University.
July 1997 – December 1998 "Journal Club," a weekly seminar presented to the staff of the "Imipramine and Relapse Prevention in Depressed Methadone Patients" research project
January 1998 "The Neurochemistry and Molecular Biology of Antidepressant Medications," course given to first and second year Child and Adolescent Psychiatry Fellows, St. Vincent’s Hospital and Medical Center, New York, NY
1995 – 1997 "Network Therapy," thirteen-week course given to third year General Psychiatry Residents at the New York University Medical Center, New York, NY
1995 – 1997 "Addiction Medicine Course"; Physician in charge of coordinating and teaching third and fourth year Medical Students, New York University Medical Center, New York, NY
1995 – 1997 Individual Weekly Psychopharmacological and Psychodynamic Psychotherapy supervision to third and fourth year General Psychiatry Residents at the New York University Medical Center, New York, NY
1995 – 1997 "Behavioral Science," eight-week course given to first year Medical Students, New York University Medical Center, New York, NY
June 1997 "Cocaine: Epidemiology, Pharmacology and Treatment," lecture given to third and fourth year Medical Students, New York University Medical Center, New York, NY
May 1997 "Cocaine: Therapeutic communities," lecture given to third and fourth year Medical Students, New York University Medical Center, New York, NY
April 1997 "The Neurobiology of Cocaine Addiction," lecture given to third and fourth year Medical Students, New York University Medical Center, New York, NY
February 1997 "Heroin: Epidemiology, Pharmacology and Treatment," lecture given to third and fourth year Medical Students, New York University Medical Center, New York, NY
January 1997 "Medical Complications of Alcoholism," lecture given to third and fourth year Medical Students, New York University Medical Center, New York, NY
December 1996 "Different Treatment Approaches to Alcoholism," lecture given to third and fourth year Medical Students, New York University Medical Center, New York, NY
October 1996 ‘Heroin: The New Crisis?" lecture given to third and fourth year Medical Students, New York University Medical Center, New York, NY
September 1996 "Ethanol and the Central Nervous System," lecture given to third and fourth year Medical Students, New York University Medical Center, New York, NY
August 1996 "Neurobiology: how it has contributed to our understanding of Opiate Addiction," lecture given to third and fourth year Medical Students, New York University Medical Center, New York, NY
March 1996 "The Neurobiology of Addictive Illnesses," lecture series given to second year Medical Students, New York University School of Medicine, New York University Medical Center, New York, NY
1994 – 1997 "Psychiatric Clinical Clerkships"; preceptor to third and fourth year Medical Students, New York University Medical Center, New York, NY
1993 – 1994 Supervision given to third and fourth year Medical Students in the Bellevue Hospital Comprehensive Psychiatric Evaluation Program

RESEARCH ACTIVITIES 1995-1997

1. Imipramine and Relapse Prevention in Depressed Methadone Patients. Co-Investigator: David Sert Krakow, M.D.
2. HIV Risk Factors in Dually Diagnosed Patients. Principal Investigator: David Sert Krakow, M.D.
3. Tuberculosis in Dually Diagnosed Patients. Principal Investigator: Tania Taubes M.D. Co-Investigator: David Sert Krakow, M.D.
4. Predictors of Treatment Outcome in Dually Diagnosed Patients. Principal Investigator: Daniel Leal, M.D. Co-Investigator: David Sert Krakow, M.D.
5. Buprenorphine in Detoxification of Opiate Addicts. Principal Investigator: William Matikiewitz, M.D.
6. Network Therapy for the Office Practitioner. Principal Investigator: Marc Galanter, M.D.
7. Cigarette Smoking Patterns in Dually Diagnosed Patients. Principal Investigator: Steven Taylor, M.D.
8. Predictors of Retention in a Modified Therapeutic Community. Principal Investigator: Daniel Mierlak, M.D.

RESEARCH GRANTS

1. A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of BMS-562086 in the Treatment of Outpatients with Major Depressive Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol-Myers Squibb Pharmaceutical Research Institute; March 2007-September 2007

2. A Multi-center, 10-Week, Randomized, Double-blind Study of Sertraline and Placebo in Children and Adolescents with Post-traumatic Stress Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer Pharmaceuticals Group; January 2003 – September 2007

3. A Multi-center, Randomized, Double-blind, Placebo-controlled Study with Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Adolescent Patients with Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc.

4. A Multi-center, Randomized, Double-blind, Placebo-controlled Study of Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Child and Adolescent Patients Aged 10–17 Years, with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc.

5. A Multi-center, Open-label Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2mg – 30mg) in the Treatment of Adolescent Patients with Schizophrenia, and Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc.

6. A Double-blind Multi-center Study Comparing The Safety and Efficacy of Ziprasidone to Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer/Scirex; April 2000 – August 2000

7. A Double-blind, 12-Month Continuation Protocol for Patients who Successfully Completed Protocol RO548. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer/Scirex; April 2000 – August 2001

8. Olanzapine Plus Fluoxetine Combination Therapy in Treatment Resistant Depression: A Dosing Range Study: Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.: Sponsor: Eli Lilly and Co.; March 2000 – July 2002

9. A Multi-center, Randomized, Double-blind Study of Flexible Doses of Aripriprazole vs. Perphenazine in the Treatment of Patients with Treatment-Resistant Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Bristol Myers Squibb; August 2000 – July 2002

10. A Multi-center, Randomized, Double-blind Study and Tolerability Study of Flexible Doses of Aripiprazole and Olanzapine in the Treatment of Patients with Acute Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Bristol Myers Squibb; October 2000 – July 2002

11. The Efficacy and Safety of Risperidone in the treatment of children and adolescents with schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D.; Sponsor: Janssen/Medex; April 2001 – July 2002

12. Olanzapine vs. Risperidone in the treatment of Bipolar I disorder, mixed or manic. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001 – July 2002

13. Olanzapine vs. Ziprasidone in the treatment of Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001 – July 2002

14. A comparison of fasting triglyceride levels cohorts with schizophrenic and related disorder treated chronically with Olanzapine, Risperidone and typical anti-psychotics. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lily & Company; August 2001 – April 2002

15. A Phase III, Randomized, Multi-center, Double-blind, Parallel-group, Placebo-controlled Safety and Efficacy Study of SPD503 in Children and Adolescents aged 6–17 with Attention Deficit Hyperactivity Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc.

16. A Phase III, Open-label Study of SPD503 in Children and Adolescents aged 6–17 with Attention Deficit Hyperactivity Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc.

17. A Phase III, Randomized, Multi-center, Double-blind, Parallel-group, Placebo-controlled Safety and Efficacy Study of ADDERALL XR® with an Open-label Extension, in the Treatment of Adolescents Aged 13–17 with Attention Deficit Hyperactivity Disorder (ADHD). Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc.

18. Olanzapine vs. Placebo in the Treatment of Mania in Adolescents with Bipolar I Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company

19. Olanzapine vs. Placebo in the Treatment of Adolescents with Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company

20. The Study of Olanzapine plus Fluoxetine in Combination for Treatment-resistant Depression Without Psychotic Features. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly & Company

21. Population Pharmacokinetic Study in Adolescent Patients with Schizophrenia or Bipolar I Disorder Treated with Olanzapine. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Eli Lilly & Company

HONORS AND AWARDS

1990 New York University School of Medicine, Department of Psychiatry, Letter of Commendation in Psychiatry Sub-internship
1990 Hahnemann University School of Medicine, Department of Neurology, Letter of Commendation in Senior Neurology Rotations1988 Hahnemann University School of Medicine, Department of Psychiatry. Fellowship and stipend awarded for the study of Alcohol, Cocaine and Heroin substance abuse in the Department of Psychiatry, University of Pennsylvania,
Philadelphia, PA
1988 Hahnemann University School of Medicine, Department of Psychiatry, Letter of Commendation in Introduction to Psychotherapy and Advanced Diagnostics
1988 Hahnemann University School of Medicine, Department of Psychiatry, Letter of Commendation in Accelerated Psychiatry Program
1987 Hahnemann University School of Medicine, Department of Psychiatry, Letter of Commendation in Associated Psychiatry Program
1987 Hahnemann University School of Medicine, Department of Psychiatry, Letter of Commendation in Psychopathology

MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

1998 – Present American Academy of Psychoanalysis
1998 – Present American College of Forensic Examiners
1996 – Present American Academy of Addiction Psychiatry
1996 – Present American Society of Addiction Medicine
1991 – Present American Psychiatric Association

COMMITTEE APPOINTMENTS

July 1994 – June 1995 Third and Fourth Year Psychiatry Residents Steering Committee, New York University Medical Center, Department of Psychiatry, New York, NY
July 1994 – June 1995 Second Year Psychiatry Residents Steering Committee, New York University Medical Center, Department of Psychiatry, New York, NY
July 1994 – June 1995 Curriculum Committee, New York University Medical Center, Department of Psychiatry, New York, NY
July 1994 – June 1995 Steering Committee, New York University Medical Center, Department of Psychiatry, New York, NY

PUBLICATION IN JOURNALS

Krakow D, Galanter M, Dermatis H, Westreich L: HIV Risk Factors in Dually Diagnosed Patients, American Journal on Addiction, 1998; 7:74 – 80.

BOOK CHAPTERS

Krakow D: Competency and Other Legal Issues.
In: Bernstein C, Ladds B, Maloney A, Weiner E,
(Ed.), On Call Psychiatry. Philadelphia, W.B.Saunders Company, pp 27 – 33.

PRESENTATIONS AND LECTURES

March 1999 "Depression: Update on Treatment," presented to the Department of Medicine, Grand Rounds, New York Downtown Hospital, New York, NY
November 1998 "The Neurobiology of Addiction," presented to the Department of Psychiatry, Grand Rounds, New York Medical College, Valhalla, NY
September 1998 "The Neurobiology of Addictive Illnesses," presented to the Department of Psychiatry, Grand Rounds, New York University Medical Center, New York, NY
June 1998 "Research Report from the APA: What’s new and Exciting," dinner symposium sponsored by Pfizer,
New York, NY
April 1998 "The Signs and Symptoms of Depression," presented at the Fifty Plus Expo, Madison Square Garden, New York, NY
March 1998 "The Neurobiology of Addiction," presented to the Department of Psychiatry, Grand Rounds, St. Vincent’s Hospital and Medical Center, New York, NY
February 1998 "Depression: What Do We Know?" presented to the Department of Medicine, Beth Israel Medical Center, New York, NY
June 1997 "Dually Diagnosed Patients in the Prison System: Evaluation and Treatment," presented at the OASIS/OMH Conference on Persons with Co-
Occurring Psychiatric and Substance Abuse Disorders in the Criminal Justice System, Albany, NY
November 1995 "Good Day America," TV show appearance offering advice on marital relationships
March 1994 "Depression: Etiology, Diagnosis and Treatment," presented at the Brystol-Myers-Squib Nefazadone National Launch, Dallas TX

WORKSHOPS ATTENDED AT COLUMBIA UNIVERSITY

1. "An interdisciplinary Perspective on Substance Abuse education," The New York State Addiction Technology Transfer Center and New York University Medical Center, New York, June 10, 1998
2. Workshop on the Addiction Severity Index and the Quantitative Substance Use Inventory (by Susan Tross Ph.D.), Columbia University, New York, NY, July 25, 1997
3. Rater Assessment Training (Hamilton Depression Scale, Beck Depression Scale, Hamilton Anxiety Scale, Clinical Global Rating) (by Susan Tross Ph.D.), Columbia University, New York, NY, July 15 – 17, 1997
4. Workshop on the Structured Clinical Interview for DSM-IV (SCID for DSM-IV) (by Susan Tross Ph.D.), Columbia University, New York, NY, July 8 – 10, 1997

WORKSHOP ATTENDED AT NEW YORK UNIVERSITY

Workshop on the Brief Psychiatric Rating Scale (BPRS) (by Marc Galanter, M.D.), November 4 – 6, 1997

OTHER WORKSHOPS ATTENDED

1. Buprenorphine Training Session: Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence, sponsored by the American Academy of Addiction Psychiatry, January 18, 2002
2. Short-term Psychoanalytically Based Psychotherapy with Dr. Davenloo, Harvard Medical School, June 16 – 21, 1994
3. Short-term Psychoanalytically Based Psychotherapy with Dr. Malan, November 14 – 16 1994, New York, NY
4. The Metapsychology of Dr. Davanloo’s Short Term Psychoanalytically Based Psychotherapy, February 24, 1993, Park City, Utah

NATIONAL MEETINGS ATTENDED

1. Association for Research in Nervous and Mental Diseases, Annual Meeting, "The Neurobiology of Psychiatry," New York, NY, December 4, 5, 1998
2. New York University Medical Center, The New York Addiction Transfer Center, "An Interdisciplinary Perspective in Substance Abuse Education," New York, NY, June 10, 1998
3. Columbia University College of Physicians and Surgeons, Center for Continuing Education, "Gender and Depression: Perspectives for the New Millennium," New York, NY, April 30 – May 1, 1998
4. American Psychopathological Association, Annual Meeting, "Childhood Onset of Adult Psychopathology," New York, NY, March 5 – 7, 1998
5. "Psychopharmacology Annual Review," New York University Medical Center, New York, NY March 7, 1998
6. American Psychiatric Association, Annual Meeting, San Diego, CA, May 17 – 22, 1997
7. American Psychiatric Association, Annual Meeting, New York, NY, May 4 – 9, 1996
8. "New Approaches to the Treatment of Alcoholism," Columbia University College of Physicians and Surgeons, New York, NY, June 21, 1995
9. American Psychiatric Association, Annual Meeting, Miami, FL, May 20 – 25, 1995
10. "Clinical Neurology for Psychiatrists," Albert Einstein College of Medicine, New York, NY, September 29 – October 1, 1995
11. New Clinical Drug Evaluation Unit Program/NCDEU, 34th Annual Meeting, Marco Island, FL, May 31 – June 3, 1994
12. American Psychiatric Association, Annual Meeting, Philadelphia, PA, May 21 – 27, 1994
13. "Mood Disorders and their Effective Treatment," Harvard Medical School, Department of Continuing Education, Boston, MA, April 2 – 4, 1993
14. Association for Research in Nervous and Mental Diseases, Annual Meeting, "Biology of Schizophrenia and Affective Disease," New York, NY, December 3, 4, 1993
15. American Psychiatric Association, Annual Meeting, Washington D.C. May 2 – 7, 1992

INTERNATIONAL MEETINGS ATTENDED

1. First International Congress on Hormones, Brain and Neuropsychopharmacology, Rhodes, Greece, September 13 – 17, 1993
2. Health Care Delivery System in France, Louis Pasteur Institute, Paris, France, May 4 – 8, 1998

top